9.2 Site Selection and Qualification

Certified Clinical Research Coordinator CCRC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Scientific Concepts and Research Design

1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics

2 Chapter 2: Ethical Principles and Guidelines

2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent

3 Chapter 3: IRB/IEC Oversight and Participant Safety

3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting

4 Chapter 4: Participant Rights and Ethics

4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials

5 Chapter 5: Product Development and Regulatory Framework

5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)

6 Chapter 6: Investigational Product Accountability

6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction

7 Chapter 7: Regulatory Submissions and Actions

7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development

8 Chapter 8: Clinical Trial Operations and GCP Principles

8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight

9 Chapter 9: Essential Documents and Site Qualification

9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)

10 Chapter 10: Protocol Deviations and Amendments

10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control

11 Chapter 11: Monitoring Visits and Audits

11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits

12 Chapter 12: Study and Site Management - Startup

12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation

13 Chapter 13: Enrollment and Recruitment

13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics

14 Chapter 14: Daily Trial Coordination

14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)

15 Chapter 15: Quality Improvement and Site Closeout

15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures

16 Chapter 16: Source Documentation and Case Report Forms

16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems

17 Chapter 17: Data Management and Queries

17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails

18 Chapter 18: Data Privacy and Records Retention

18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics

9.2 Site Selection and Qualification

Key Takeaways Explain This Topic AI

Site selection evaluates a site's capability to conduct the trial, balancing feasibility, patient access, and staff qualifications.

Feasibility questionnaires gather preliminary data on site infrastructure, past trial performance, and target population.

Pre-Study Visits (PSVs) or Site Qualification Visits (SQVs) are conducted by CRAs to verify site capabilities and facilities.

A Confidentiality Disclosure Agreement (CDA) must be fully executed before the sponsor shares the study protocol with the PI.

PI qualifications, including therapeutic expertise and time availability, are critical factors in the qualification process.

Last updated: October 2026

9.2 Site Selection and Qualification

Quick Answer: Site selection is a multi-step process employed by sponsors and Contract Research Organizations (CROs) to identify and evaluate investigative sites. The goal is to determine if a site has the necessary patient population, qualified staff, and appropriate facilities to successfully conduct a clinical trial in compliance with GCP.

Before a site can officially begin enrolling patients in a clinical trial, it must undergo a rigorous evaluation process known as Site Selection and Qualification. This phase involves extensive communication between the site and the sponsor/CRO, beginning with initial contact and culminating in a formal Pre-Study Visit (PSV) or Site Qualification Visit (SQV).

1. Initial Contact and Confidentiality

The process typically begins when a sponsor or CRO reaches out to a Principal Investigator (PI) who has relevant therapeutic experience. At this stage, the sponsor only provides a high-level summary of the study to gauge the PI's interest.

Confidentiality Disclosure Agreement (CDA)

Before the sponsor can share proprietary information, such as the full clinical study protocol or the Investigator's Brochure (IB), a Confidentiality Disclosure Agreement (CDA)—sometimes called a Non-Disclosure Agreement (NDA)—must be signed. The CDA legally binds the site and its staff to keep the study details confidential and not to use the information for any purpose other than evaluating their interest and capability to participate in the trial.

2. The Feasibility Questionnaire

Once the CDA is executed, the sponsor provides the protocol and a feasibility questionnaire. The site coordinator and PI must complete this comprehensive document accurately. It assesses several critical domains:

Patient Population: Can the site meet the enrollment targets? How many patients with the specific inclusion/exclusion criteria does the PI treat per month?

Site Infrastructure: Does the site have the necessary equipment (e.g., -80°C freezers, ECG machines, refrigerated centrifuges)?

Staffing: Are there sufficient Clinical Research Coordinators (CRCs), sub-investigators, and unblinded pharmacists available?

Past Performance: What is the site's track record with similar trials? Have they successfully met enrollment goals in the past?

IRB/Regulatory Timelines: Does the site use a central IRB, or must they rely on a slower local institutional IRB? What are the typical contract execution timelines?

Real-World Example

Consider a cardiovascular outcomes trial requiring 50 randomized patients per site over a 12-month period. A site might treat hundreds of cardiovascular patients, but the feasibility questionnaire must narrow this down to patients meeting specific lipid criteria who have also had a recent myocardial infarction. Overestimating enrollment capabilities at this stage is a common pitfall that can lead to poor performance later.

3. Site Qualification Visit (SQV) / Pre-Study Visit (PSV)

If the feasibility questionnaire demonstrates potential, the sponsor will schedule a Site Qualification Visit (SQV), also known as a Pre-Study Visit (PSV). A Clinical Research Associate (CRA) will travel to the site (or conduct a remote visit) to verify the information provided in the feasibility questionnaire and evaluate the site firsthand.

Key Objectives of the SQV

During the SQV, the CRA will evaluate:

PI Qualifications and Engagement: The CRA will interview the PI to assess their understanding of the protocol, their therapeutic expertise, and their actual availability to oversee the trial (as required by GCP).

Facility Tour: The CRA will inspect the clinical areas where patients will be seen, the laboratory processing areas, and the Investigational Product (IP) storage facilities. IP storage must have restricted access and temperature monitoring.

Archiving and Storage: The site must have adequate, secure space to store essential documents (the ISF) and source documents both during and after the trial.

Ancillary Services: If the protocol requires specific procedures like MRIs, DEXA scans, or specialized infusions, the CRA will evaluate these ancillary departments for capacity and GCP compliance.

Evaluation and Outcome

Following the SQV, the CRA writes a detailed report recommending whether the site should be selected. The sponsor makes the final decision based on the CRA's report, the site's feasibility data, and overall study needs. If selected, the site moves to the start-up phase, involving budget negotiations, contract execution, and regulatory document collection, culminating in the Site Initiation Visit (SIV).

4. Common Reasons for Site Rejection

Not all sites that undergo an SQV are selected. Common reasons for rejection include:

Lack of Access to Target Population: The PI's database does not support the required enrollment numbers.

Inadequate Facilities: Poor drug storage security, lack of necessary equipment, or insufficient space for monitoring visits.

PI Unavailability: The PI is stretched too thin across multiple trials and cannot provide adequate medical oversight.

Historical Non-Compliance: The site has a history of major GCP violations or FDA warning letters.